Optimisation of the microplate resazurin assay for screening and bioassay-guided fractionation of phytochemical extracts against mycobacterium tuberculosis

Phytochemical Analysis

Volumn 25, Issue 5, 2014, Pages 461-467

  O'Neill, Taryn E ^a   Li, Haoxin ^a   Colquhoun, Caitlyn D ^a   Johnson, John A ^a   Webster, Duncan ^b   Gray, Christopher A ^a  

^a UNIVERSITY OF NEW BRUNSWICK   (Canada)

^b SAINT JOHN REGIONAL HOSPITAL   (Canada)

Author keywords

anti mycobacterial activity; bioassay screening; bioassay guided fractionation; medicinal plants; microplate resazurin assay; Mycobacterium tuberculosis H37Ra

Indexed keywords

ORGANIC SOLVENTS; TUBES (COMPONENTS);

ANTI-MYCOBACTERIAL; ANTI-MYCOBACTERIAL ACTIVITY; BIOASSAY SCREENING; BIOASSAY-GUIDED FRACTIONATION; MEDICINAL PLANTS; MICROPLATE RESAZURIN ASSAY; MICROPLATES; MYCOBACTERIUM TUBERCULOSIS H37RA; PHYTOCHEMICAL; RESAZURIN;

BIOASSAY;

ACORUS CALAMUS EXTRACT; ALNUS INCANA EXTRACT; ANTIMYCOBACTERIAL AGENT; ARALIA NUDICAULIS EXTRACT; EMPETRUM NIGRUM EXTRACT; FRAGARIA VIRGINIANA EXTRACT; GEUM MACROPHYLLUM EXTRACT; HERACLEUM MAXIMUM EXTRACT; HYPERICUM PERFORATUM EXTRACT; JUNIPERUS COMMUNIS EXTRACT; METHANOL; MONESES UNIFLORA EXTRACT; NUPHAR LUTEA EXTRACT; PLANT MEDICINAL PRODUCT; POPULUS TREMULOIDES EXTRACT; RESAZURIN; SARRACENIA PURPUREA EXTRACT; SYMPLOCARPUS FOETIDUS EXTRACT; UNCLASSIFIED DRUG; OXAZINE DERIVATIVE; PLANT EXTRACT; RIFAMPICIN; TUBERCULOSTATIC AGENT; XANTHENE DERIVATIVE;

ACORUS CALAMUS; ALNUS INCANA; ANTIMICROBIAL ACTIVITY; ARALIA NUDICAULIS; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; EMPETRUM NIGRUM; EXTRACTION; FRACTIONATION; FRAGARIA VIRGINIANA; GEUM MACROPHYLLUM; HERACLEUM MAXIMUM; HYPERICUM PERFORATUM; JUNIPERUS; MEDICINAL PLANT; MONESES UNIFLORA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUPHAR LUTEA; POPULUS TREMULOIDES; RESAZURIN ASSAY; SARRACENIA PURPUREA; SCREENING; SYMPLOCARPUS FOETIDUS; ANGIOSPERM; BIOASSAY; CHEMISTRY; DRUG EFFECTS;

MYCOBACTERIUM TUBERCULOSIS;

ANGIOSPERMS; ANTITUBERCULAR AGENTS; BIOLOGICAL ASSAY; CHEMICAL FRACTIONATION; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; PLANT EXTRACTS; RIFAMPIN; XANTHENES;

EID: 84906936650     PISSN: 09580344     EISSN: 10991565     Source Type: Journal    
DOI: 10.1002/pca.2516     Document Type: Article

References (39)

1. Banfi E, Scialino G, Zampieri D, Mamolo MG, Vio L, Ferrone M, Fermeglia M, Paneni MS, Pricl S,. 2006. Antifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined experimental and computational approach. J Antimicrob Chemother 58 (1): 76-84.
2. Carpenter CD, O'Neill T, Picot N, Johnson JA, Robichaud GA, Webster D, Gray CA,. 2012. Anti-mycobacterial natural products from the Canadian medicinal plant Juniperus communis. J Ethnopharmacol 143 (2): 695-700.
3. Coelho RG, Honda NK, Vieira MdC, Brum RL, Pavan FR, Fujimura Leite CQ, Lima Cardoso CA,. 2010. Chemical composition and antioxidant and antimycobacterial activities of Bromelia balansae (Bromeliaceae). J Med Food 13 (5): 1277-1280.
4. Collins LA, Franzblau SG,. 1997. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41 (5): 1004-1009.
5. Copp BR,. 2003. Antimycobacterial natural products. Nat Prod Rep 20 (6): 535-557.
6. Copp BR, Pearce AN,. 2007. Natural product growth inhibitors of Mycobacterium tuberculosis. Nat Prod Rep 24 (2): 278-297.
7. Garcia A, Bocanegra-Garcia V, Prisco Palma-Nicolas J, Rivera G,. 2012. Recent advances in antitubercular natural products. Eur J Med Chem 49: 1-23.
8. Gray CA, Johnson JA, Webster D,. 2013. Canadian traditionally used medicinal plants: can they play a role in antituberculosis drug development? Future Med Chem 5 (8): 853-855.
9. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K,. 2011. The challenge of new drug discovery for tuberculosis. Nature 469 (7331): 483-490.
10. Lawn SD, Zumla AI,. 2011. Tuberculosis. Lancet 378 (9785): 57-72.
11. Lemus D, Martin A, Montoro E, Portaels F, Palomino JC,. 2004. Rapid alternative methods for detection of rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 54 (1): 130-133.
12. Li H, O'Neill T, Webster D, Johnson JA, Gray CA,. 2012. Anti-mycobacterial diynes from the Canadian medicinal plant Aralia nudicaulis. J Ethnopharmacol 140 (1): 141-144.
13. Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuens J,. 2012. New drugs for the treatment of tuberculosis: Needs, challenges, promise, and prospects for the future. J Infect Dis 205: S241-S249.
14. Lu XY, Liu XB, Wan BJ, Franzblau SG, Chen LL, Zhou CL, You QD,. 2012. Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2. Eur J Med Chem 49: 164-171.
15. Martin A, Camacho M, Portaels F, Palomino JC,. 2003. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: Rapid, simple, and inexpensive method. Antimicrob Agents Chemother 47 (11): 3616-3619.
16. Martin A, Morcillo N, Lemus D, Montoro E, da Silva Telles MA, Simboli N, Pontino M, Porras T, Leõn C, Velasco M, Chacon L, Barrera L, Ritacco V, Portaels F, Palomino JC,. 2005. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 9 (8): 901-906.
17. McCutcheon AR, Stokes RW, Thorson LM, Ellis SM, Hancock REW, Towers GHN,. 1997. Anti-mycobacterial screening of British Columbian medicinal plants. Int J Pharm 35 (2): 77-83.
18. Migliori GB, Centis R, D'Ambrosio L, Spanevello A, Borroni E, Cirillo DM, Sotgiu G,. 2012. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 54 (9): 1379-1380.
19. Newman DJ, Cragg GM,. 2012. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75 (3): 311-335.
20. O'Brien RJ, Nunn PP,. 2001. The need for new drugs against tuberculosis. Am J Respir Crit Care Med 163 (5): 1055-1058.
21. O'Neill TE,. 2012. Antimycobacterial natural products from Heracleum maximum. MSc thesis, University of New Brunswick; 126 pp. Available at http://hdl.handle.net/1882/45621.
22. O'Neill TE, Webster D, Johnson JA, Gray CA,. 2013. The Canadian medicinal plant Heracleum maximum contains antimycobacterial diynes and furanocoumarins. J Ethnopharmacol 147 (1): 232-237.
23. Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F,. 2002. Resazurin microtiter assay plate: Simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46 (8): 2720-2722.
24. Primm TP, Franzblau SG,. 2007. Recent advances in methodologies for the discovery of antimycobacterial drugs. Curr Bioact Compd 3 (3): 201-208.
25. Salomon CE, Schmidt LE,. 2012. Natural products as leads for tuberculosis drug development. Curr Top Med Chem 12 (7): 735-765.
26. Schafer MP, Fernback JE, Ernst MK,. 1999. Detection and characterization of airborne Mycobacterium tuberculosis H37Ra particles, a surrogate for airborne pathogenic M. tuberculosis. Aerosol Sci Technol 30 (2): 161-173.
27. Sivakumar A, Jayaraman G,. 2011. Anti-tuberculosis activity of commonly used medicinal plants of south India. J Med Plant Res 5 (31): 6881-6884.
28. Sokal RR, Rohlf FJ,. 1995. Biometry: The Principles and Practice of Statistics in Biological Research. W. H. Freeman and Company: New York, NY; 880 pp.
29. Twigg RS,. 1945. Oxidation-reduction aspects of resazurin. Nature 155 (3935): 401-402.
30. Van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE,. 2009. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 53 (3): 849-862.
31. Vanitha JD, Paramasivan CN,. 2004. Evaluation of microplate Alamar Blue assay for drug susceptibility testing of Mycobacterium avium complex isolates. Diagn Microbiol Infect Dis 49 (3): 179-182.
32. Villemagne B, Crauste C, Flipo M, Baulard AR, Deprez B, Willand N,. 2012. Tuberculosis: The drug development pipeline at a glance. Eur J Med Chem 51: 1-16.
33. Voelker R,. 2013. MDR-TB has new drug foe after fast-track approval. J Amer Med Assoc 309 (5): 430-430.
34. Webster D, Lee TDG, Moore J, Manning T, Kunimoto D, LeBlanc D, Johnson JA, Gray CA,. 2010. Antimycobacterial screening of traditional medicinal plants using the microplate resazurin assay. Can J Microbiol 56 (6): 487-494.
35. WHO. 2012. Global tuberculosis report 2012. 272 pp.
36. Zar JH,. 2010. Biostatistical Analysis. Prentice Hall: Upper Saddle River, NJ; 960 pp.
37. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, Squire SB, Cox, H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O'Grady J, Pletschette M, Ramsay A, Chakaya J, Schito M, Swaminathan S, Memish Z, Maeurer M, Atun R,. 2012a. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 205: S228-S240.
38. Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A,. 2012b. Advancing the development of tuberculosis therapy. Nat Rev Drug Discovery 11 (3): 170-171.
39. Zumla A, Raviglione M, Hafner R, von Reyn CF,. 2013. Tuberculosis. N Engl J Med 368 (8): 745-55.